会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • GLUCAGON RECEPTORS
    • GLUCAGON受体
    • WO1994005789A1
    • 1994-03-17
    • PCT/US1993008174
    • 1993-08-30
    • ZYMOGENETICS, INC.
    • ZYMOGENETICS, INC.KINDSVOGLE, Wayne, R.JELINEK, Laura, J.SHEPPARD, Paul, O.GRANT, Francis, J.KUIJPER, Joseph, L.FOSTER, Donald, C.LOK, SiO'HARA, Patrick, J.
    • C12N15/12
    • C07K14/723A61K38/00C07K14/72C07K2319/00C07K2319/02C12Q1/66G01N33/74G01N2333/605G01N2333/72
    • The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs. The present invention also provides amethod for detecting the presence of glucagon antagonists, comprising the steps of (a) exposing a compound in the presence of a glucagon agonist to a recombinant glucagon receptor coupled to a response pathway under conditions and for time sufficient to allow binding of the compound to the receptor and an associated response through the pathway, and (b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the glucagon receptor, relative to the stimulation of the response pathway by the glucagon agonist alone and therefrom determining the presence of a glucagon antagonist.
    • 本发明提供了分离的DNA分子,其包含编码胰高血糖素受体的DNA区段。 还提供了DNA构建体,其包含编码与第一DNA片段表达所需的另外DNA片段可操作地连接的胰高血糖素受体的第一DNA片段,以及含有该DNA构建体的宿主细胞。 本发明还提供了检测胰高血糖素拮抗剂的存在的方法,其包括以下步骤:(a)在有足够的条件和足以允许结合的时间内将化合物在胰高血糖素激动剂存在下暴露于与响应途径偶联的重组胰高血糖素受体 化合物与受体的相关反应和通过该途径的相关应答,以及(b)检测由化合物与胰高血糖素受体的结合产生的反应途径的刺激相对于由 胰高血糖素激动剂单独和由此决定胰高血糖素拮抗剂的存在。
    • 8. 发明申请
    • LOW MOLECULAR WEIGHT THROMBOPOIETIN
    • 低分子重量血小板计数
    • WO1996017062A1
    • 1996-06-06
    • PCT/US1995014929
    • 1995-11-15
    • ZYMOGENETICS, INC.
    • ZYMOGENETICS, INC.BUDDLE, Michele, M.DOWNEY, WilliamFOSTER, Donald, C.FORSTROM, John, W.LOK, SiOSBORN, Sherri, G.
    • C12N15/19
    • C07K14/524A01K2217/05A61K38/00
    • Isolated mammalian thrombopoietins are disclosed. The thrombopoietins include polypeptides characterized by an amino acid sequence selected from the group consisting of (a) a sequence of amino acids as shown in SEQ ID NO:2 having an amino terminus at Ser(45) and a carboxyl terminus between Ser(208) and Asn(216), inclusive; a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus between Arg(185) and Asn(193), inclusive; a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Arg(198); a sequence of amino acids as shown in SEQ ID NO:4 having an amino terminus at Ser(22) and a carboxyl terminus at Phe(207); and allelic variants of (a)-(d). Also disclosed are isolated DNA molecules encoding these polypeptides as well as vectors, cells and methods that can be used for the production of the polypeptides.
    • 公开了分离的哺乳动物血小板生成素。 血小板生成素包括以氨基酸序列为特征的多肽,所述氨基酸序列选自(a)SEQ ID NO:2所示氨基酸序列,其具有Ser(45)的氨基末端和Ser(208)之间的羧基末端, 和Asn(216)(含); 如SEQ ID NO:4所示的氨基酸序列,其具有Ser(22)的氨基末端和Arg(185)和Asn(193)之间的羧基末端(包括端值); 如SEQ ID NO:4所示的氨基酸序列,其在Ser(22)具有氨基末端,在Arg处具有羧基末端(198); 如SEQ ID NO:4所示的氨基酸序列,其在Ser(22)具有氨基末端,在Phe(207)具有羧基末端; 和(a) - (d)的等位变体。 还公开了编码这些多肽的分离的DNA分子以及可用于产生多肽的载体,细胞和方法。